Isnt this med dead now? Or was it researching still or what?
1 Like
It’s still on track to be released.
1 Like
If this works I think we will be like depressed and bipolar people, largely able to lead meaningful lives while held back mostly when symptomatic. The nature of this forum will totally change!!
1 Like
Tell me more about this med? Is it based on the dopamine hypothesis of sz?
https://www.tandfonline.com/doi/full/10.1080/14737175.2016.1174577
“ITI-007 has a unique pharmacological profile, combining potent 5-HT2a receptor antagonism with cell-type-specific dopamine and glutamate receptor modulation, plus serotonin reuptake inhibition. At dopamine-D2 receptors, ITI-007 acts as a post-synaptic antagonist and pre-synaptic partial agonist. Additionally, ITI-007 stimulates phosphorylation of glutamatergic NMDA-NR2B receptors, downstream of dopamine-D1 receptor intracellular signaling.”
2 Likes
Sounds like Abilify without the nmda activity. How do u feel about it, twinkle?
It seems very interesting. The best thing about it seems to be the lack of extrapyramidal side effects, weight gain etc. It does have side effects, as reported in the clinical trials - most commonly sedation or insomnia. Some other side effects as well, occuring in relatively small percentages of people.
I’d be willing to try it, probably.
2 Likes
Wasn’t there a user here that was part of the trials?
I can’t remember her name, but she was very active for a brief time.
Do u mean @Saywhaat?
1 Like
Yes @Saywhaat . She wasn’t doing so well on iti-007 then dropped off the radar. I hope she’s ok.
3 Likes
Havent heard from her in at least 2 weeks. 
1 Like
I think @eighteyedspy23 was too ??
1 Like
this drug really sounds good compared to what other options we currently have. I love no EPS. fine with sedation but not insomnia. Best thing works on negative symptoms too. Hope no side effects part is accurate.
2 Likes
Hope is works as promised:
However, in a second phase 3 trial of ITI-007 in schizophrenia patients, the drug did not differ significantly from placebo in its effect on the primary endpoint (the change from baseline in the PANSS score), whereas the active control, risperidone, did separate from placebo. Intra-Cellular Therapies blamed ITI-007’s poor showing on an unusually high placebo response rate (even though this response did not affect risperidone).26
If ITI-007 gains FDA approval, analysts anticipate that it will be launched in the U.S. in the first half of 2018.
1 Like
There has been no application yet. The company was to meet with FDA this month about planning. The NDA / New Drug Application is expected around mid year. If approved, it could be out in early 2019.
3 Likes
Shaken , not stirred.
2 Likes
It’s being branded as a heavyweight contender but time will tell if it can go the distance.
2 Likes